Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people living with Tourette Syndrome, marking a major milestone in the development of drug-free, non-invasive therapy for this condition.

Developed with the design and engineering support of Ensera Design, a global healthcare innovation consultancy, the breakthrough wearable integrates Neupulse’s neurotechnology expertise into a discreet, everyday device activated at the touch of a button.

Developed over four years but built on two decades of research by the team behind the product, the wrist-worn device uses gentle, rhythmic electrical stimulation of the median nerve to target brain networks associated with tics. Originating from pioneering neuroscience research at the University of Nottingham, the technology has shown promising results in clinical trials, demonstrating significant reductions in tic severity and frequency for both motor and phonic tics.

“This wearable and self-managed treatment could change the lives of people living with Tourette’s. It potentially offers a flexible and accessible option for the many people who are currently struggling to access treatment.” said Emma McNally, CEO of UK charity Tourettes Action.

Ensera Design’s UK team, formerly Kinneir Dufort, supported the development of the device. This included the development of an early-stage prototype for use in clinical studies, and ongoing refinements to enhance real-world usability, comfort and convenience ahead of commercial launch, enabling the device to integrate seamlessly into users’ daily lives. The partnership reflects a shared commitment to advancing inclusive healthcare solutions through cutting-edge device innovation.

“Ensera Design has been a critical partner for Neupulse in developing the Neupulse device. Vital to the relationship is a shared understanding and vision of changing the lives of people living with Tourette Syndrome,” said Paul Cable, CEO, Neurotherapeutics Ltd.

“Turning pioneering research into a functional medical device that’s ready for commercial launch is no small task,” said Kerry Briggs, VP Design and Development Europe at Ensera Design. “It was essential that our design, electronics engineering and prototyping experts worked in lockstep with the Neurotherapeutics team. Getting a product to perform in real-world use calls for more than just deep technical expertise. It requires a strong sense of shared commitment to the people we’re designing for – something which drove us from the outset of this important project.”

“It’s rare to work on an innovation that so directly improves lives,” said Craig Wightman, Chief Design Officer at Ensera Design during the development of the project. “From the outset, we felt a deep responsibility to help bring this therapy from the lab to life in a form that’s usable, effective, and human-centred.”

The announcement comes amid growing awareness of Tourette Syndrome, partly driven by the release of the film I Swear, inspired by the real-life story of John Davidson, a long-term advocate for greater understanding and acceptance of Tourettes. The film has helped shine a light on the lived experiences of people with Tourette Syndrome and the need for accessible, evidence-based therapies that provide non-invasive relief.

Regulatory submissions for the device are currently underway, with commercial availability targeted for 2026.

“The Neupulse device is more than an engineering success, it’s a cultural and clinical turning point for people with Tourette Syndrome,” added Wightman.

Ensera Design is a global healthcare innovation partner formed from the integration of Kinneir Dufort and HS Design. With studios in the UK and US, we specialize in human-centred MedTech, pharmaceutical, and consumer health product design and development. Backed by the Ensera Group, our team delivers safe, effective, market-ready solutions that improve health outcomes, with a commitment to quality, sustainability, and global regulatory standards. For more information, visit: www.enseradesign.com

Neupulse is a neurotechnology company pioneering non-invasive neuromodulation solutions to improve quality of life for people living with neurological and mental health conditions. Combining neuroscience and user-centric design, Neupulse develops wearable technologies that deliver effective and drug free solutions. Our mission is to make clinically validated neuromodulation therapies available to everyone, empowering individuals to take control of their neurological health. For more information, visit www.neupulse.co